Prescient Therapeutics Raises $8m for cancer treatment therapies
- Prescient Therapeutics (PTX) is looking to raise $8 million via a share purchase plan (SPP) to progress its PTX-100 and PTX-200 cancer treatment therapies
- The company will also use the funds to progress its cell therapies to first-in-human clinical studies
- Under the SPP, shareholders will be able to subscribe for $30,000 worth of new shares at 17.5 cents per share
- Prescient CEO and Managing Director Steven Yatomi-Clarke says the company is seeking to maintain its momentum of “incredible” growth and its position at the forefront of oncology innovation
- Shares in PrescientTherapeutics are down 14.3 per cent and trading at 18 cents at 2:51 pm AEST
